This Month in Derm: May 2026 Podcasts

From microbiome science and psychodermatology to precision immunology and rare pediatric disease advocacy, this month’s dermatology podcasts highlighted how rapidly the specialty is evolving beyond traditional clinical boundaries. Across conversations, experts emphasized a common theme: improving patient outcomes increasingly depends on understanding dermatologic disease within a broader biologic, psychosocial, and multidisciplinary context.

Derm Dispatch: The Gut-Skin Connection and the Future of the Microbiome

In a recent episode of Derm Dispatch, Rajani Katta, MD, joined Renata Block, DMSc, MMS, PA-C, to discuss the expanding role of the gut microbiome in dermatologic disease and the growing interest in prebiotics, probiotics, and dietary interventions as supportive tools in skin health management.

Katta distinguished prebiotics—dietary substances that nourish beneficial microbes—from probiotics, the live microorganisms found in fermented foods such as yogurt, kefir, kimchi, and miso. While enthusiasm surrounding microbiome-directed therapies continues to grow, she emphasized that the science remains complex, particularly in inflammatory diseases such as atopic dermatitis (AD).

The discussion explored emerging evidence suggesting potential benefits of probiotic supplementation in AD, acne, and rosacea, while also underscoring the limitations of current research due to variability in bacterial strains, dosing, and patient response. Katta noted that future dermatologic care may eventually incorporate individualized microbiome analysis to guide treatment decisions.

At the same time, both speakers stressed the importance of evidence-based counseling amid widespread online misinformation, reinforcing that microbiome therapies should complement—not replace—comprehensive dermatologic care.

MORE FROM DERMATOLOGY TIMES NP/PA CONNECT

Skin & Psych: Rethinking Atopic Dermatitis and Chronic Itch

On Skin & Psych, host Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, welcomed dermatologist and itch expert Matthew Zirwas, MD, for a wide-ranging discussion on atopic dermatitis, psychodermatology, and the environmental factors shaping chronic inflammatory skin disease.

Zirwas challenged several longstanding assumptions in dermatology, proposing that many cases of AD may reflect acquired barrier dysfunction driven by modern environmental exposures—including pollution, hard water, chemical irritants, and frequent bathing—rather than purely inherited disease. He also explored the overlap between AD and allergic contact dermatitis, suggesting that environmentally triggered barrier dysfunction may play a larger role than traditionally recognized.

A major focus of the episode centered on chronic itch management and patient communication. Zirwas discussed his use of mirtazapine for nocturnal pruritus, emphasizing both its antihistaminic properties and the importance of carefully framing treatment discussions to reduce stigma and improve adherence.

Throughout the conversation, curiosity, empathy, and patient-centered education emerged as recurring themes, alongside the importance of questioning dogma and continually reassessing evolving evidence.

MORE FROM OUR SISTER PUBLICATION PSYCHIATRIC TIMES

Don’t Be Rash: Supporting Families Through Sturge-Weber Syndrome

A recent episode of Don’t Be Rash examined the challenges families face following a diagnosis of Sturge-Weber syndrome (SWS), featuring Karen Ball, CEO of the Sturge-Weber Foundation (SWF), and Julia Terrell, the organization’s director of community relations.

The conversation explored how port-wine birthmarks, while often initially viewed as cosmetic findings, may signal a far more complex neurocutaneous disorder involving glaucoma, seizures, and neurologic disease. Both Ball and Terrell shared personal experiences as mothers of children with SWS, shaping the foundation’s patient-centered mission and advocacy efforts.

The episode highlighted the importance of early ophthalmologic and neurologic evaluation, multidisciplinary care coordination, and access to specialized expertise through the SWF Clinical Care Network. The discussion also underscored the growing role patient advocacy organizations play in advancing research, supporting families, and connecting patients with informed clinical care closer to home.

MORE ON PEDIATRIC DERMATOLOGY

Don’t Be Rash: Down Syndrome and the Future of Mechanism-Based Dermatology

In another episode of Don’t Be Rash, pediatric dermatologist Jillian Rork, MD, joined host Andrew C. Krakowski, MD, to discuss the cutaneous manifestations of Down syndrome and the expanding understanding of the condition’s underlying immunologic and genetic drivers.

The conversation reviewed familiar dermatologic associations—including alopecia areata, hidradenitis suppurativa, folliculitis, and atopic dermatitis—while moving beyond descriptive diagnosis toward mechanistic understanding. Central to the discussion was the concept of gene dosage in trisomy 21 and its relationship to immune dysregulation, particularly involving interferon signaling pathways located on chromosome 21.

Rork highlighted how translational research is reshaping understanding of inflammatory disease in patients with Down syndrome, reframing previously isolated observations into part of a broader immunogenetic framework. The episode reflected a larger shift occurring throughout dermatology: integrating genomics and immunology into everyday clinical care and future therapeutic development.

MORE EPISODES OF DON’T BE RASH

Derm Dispatch: Allergy, Atopic Disease, and Cross-Specialty Care

In another episode of Derm Dispatch, allergist Zachary Rubin, MD, joined host Renata Block, DMSc, MMS, PA-C, to discuss the intersection of allergy and dermatology, with particular focus on atopic dermatitis and food allergy misconceptions.

Rubin addressed the persistent belief that food elimination alone improves eczema, emphasizing that evidence does not support routine dietary restriction for most patients and that avoidance may actually increase long-term food allergy risk. The discussion also explored the atopic march and the systemic immune mechanisms linking eczema, food allergy, allergic rhinitis, and asthma.

Looking ahead, Rubin reviewed emerging therapies including Janus kinase inhibitors, omalizumab, and investigational approaches targeting IgE-producing plasma cells. The episode reinforced the importance of patient education, multidisciplinary collaboration, and evidence-based counseling in managing complex atopic disease.

MORE FROM DERMATOLOGY TIMES NP/PA CONNECT

The Cutaneous Connection: A New Era of Oral Systemic Therapy in Psoriasis

On The Cutaneous Connection, Dermatology Times revisited an interview from the 2026 American Academy of Dermatology Annual Meeting featuring Liza O'Dowd, MD, discussing newly approved icotrokinra (Icotyde; Johnson & Johnson), the first oral IL-23 receptor antagonist peptide approved for moderate to severe plaque psoriasis.

O'Dowd reviewed long-term ICONIC trial data demonstrating sustained efficacy through 52 weeks, including high rates of complete skin clearance in both adults and adolescents. The discussion also highlighted the therapy’s emerging safety profile, minimal laboratory monitoring requirements, and reduced pre-treatment screening burden compared with many traditional systemic agents.

Beyond the clinical data, the episode explored how oral biologic-level therapies may reshape treatment preferences for both patients and clinicians, particularly among individuals seeking highly effective non-injectable options.

MORE ON PSORIASIS

The Bottom Line

This month’s podcast conversations reflected a specialty increasingly shaped by systems thinking—where dermatology intersects with immunology, psychiatry, nutrition, genetics, allergy, and patient advocacy. Whether examining the microbiome, challenging assumptions about chronic inflammatory disease, or advancing precision therapeutics, the field continues moving toward a more integrated and individualized model of care.

Like our podcasts, have suggestions, or want to participate in future episodes? Contact our team at [email protected].